Skip to main content
OpenTrials
Completed

NCT Number: NCT01905670

Safety and Performance of Electrodes Implanted in the Left Ventricle

The study is intended to demonstrate the safe implant of small receiver-electrodes into the endocardial surface of the left ventricle and to demonstrate its utility in providing cardiac resynchronization therapy in heart failure patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Na Homolce Hospital, Prague, Czechia

Loading trial locations.

About this study

Eligible patients will undergo an acoustic window assessment using transthoracic echocardiography. Patients with adequate acoustic windows will undergo implantation of the WiCS-LV system.

Patients will undergo evaluations pre-hospital discharge, and at one month, 3 months, and 6 months post implantation. Extended follow-up will be obtained via a registry at 1, 2, 3, 4, and 5 years post implantation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with standard indications for CRT based upon the most recent ESC/EHRA guidelines AND meeting criteria for one of these two categories:

  • Patients with previously implanted pacemakers or ICD's and meeting standard indications for CRT but in whom standard CRT is not advisable due to known high risk - referred to as "upgrades". Justifications for not using standard CRT must be documented in a CRF.
  • Patients in whom coronary sinus lead implantation or attempted implantation for CRT has failed to provide demonstrable therapy benefit - referred to as "untreated"

Exclusion criteria

  • Inability to comply with the study follow-up or other study requirements
  • History of chronic alcohol/drug abuse and currently using alcohol/drugs
  • Non-ambulatory (or unstable) NYHA class 4
  • Contraindication to heparin
  • Contraindication to both chronic anticoagulants and antiplatelet agents
  • Triple anticoagulation therapy (warfarin, clopidogrel, ASA, and other agents)
  • Thrombocytopenia (platelet count <150,000)
  • Contraindication to iodinated contrast agents
  • Intracardiac thrombus by transesophageal echocardiography
  • Age less than 18 years or greater than 75
  • Attempted IPG implant within 3 days
  • Life expectancy of less than 12 months
  • Chronic hemodialysis
  • Stage 4 or 5 renal dysfunction defined as GFR <30
  • Grade 4 mitral valve regurgitation
  • Myocardial infarction within one month
  • Major cardiac surgery within one month
  • History of a pericardial effusion in prior procedures
  • Female of childbearing potential, pregnant, or breastfeeding (a pregnancy test will be obtained where applicable)
  • Non-cardiac implanted electrical stimulation therapy devices

Treatment and study plan

WiCS-LV system

Device

Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator

Other names: Implant

Primary outcomes

  1. Number of patients with device-related adverse events as a measure of safety

    Time frame: 24 hour peri-operative and one month

    Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.

  2. Number of patients with procedure-related adverse events as a measure of safety

    Time frame: 24 hour perioperative and one month

    Procedure-related adverse events are those which occur during the WiCS-LV system implant procedure.

  3. Bi-ventricular pacing capture

    Time frame: one month

    Bi-ventricular pacing capture documented on 12-lead EKG

Secondary outcomes

  1. Number of patients with device-related adverse events as a measure of safety

    Time frame: 6 months

    Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.

  2. Number of patients with serious adverse events as a measure of safety

    Time frame: 6 months

  3. Bi-ventricular pacing capture

    Time frame: 6 months

    Bi-ventricular pacing capture documented on 12-lead EKG

  4. Clinical composite score

    Time frame: 6 months

    Composite of all cause mortality, heart failure hospitalization, NYHA class, and patient global assessment

  5. Change in echocardiographic indices

    Time frame: 6 months

    change in left-ventricular end-systolic volume, left ventricular end-diastolic volume, and ejection fraction

Sponsors and collaborators

Lead sponsor

EBR Systems, Inc.

Industry

Registry information

Official study title

Multicenter, Prospective Evaluation of Safety and Performance of the WiCS-LV System in Patients Indicated for Cardiac Resynchronization Therapy

Acronym: SELECT-LV

Important dates

Study start
2013
Primary completion
2015
Study completion
2019
First posted
Jul 23, 2013
Registry last updated
Jul 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.